Mapping the 25-item national eye institute visual functioning questionnaire (NEI VFQ-25) to EQ-5D utility scores

Ophthalmic Epidemiology

Volumn 21, Issue 2, 2014, Pages 66-78

  Kay, Stephen ^a   Ferreira, Alberto ^b  

^a ADELPHI REAL WORLD   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

DME; EQ 5D; Mapping; NEI VFQ 25; Visual functioning

Indexed keywords

ADULT; ALGORITHM; ARTICLE; CLINICAL OBSERVATION; CORRELATION COEFFICIENT; DIABETIC MACULAR EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; UNITED KINGDOM; VISUAL IMPAIRMENT;

ALGORITHMS; DIABETIC RETINOPATHY; FEMALE; HEALTH STATUS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; MODELS, STATISTICAL; NATIONAL EYE INSTITUTE (U.S.); QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SICKNESS IMPACT PROFILE; UNITED STATES; VISUAL ACUITY;

EID: 84896265700     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.3109/09286586.2014.888456     Document Type: Article

References (27)

1. Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health: J Int Soc Pharmacoeconom Outcomes Res 2011;14:102-109.
2. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008.
3. Longworth L, Rowen D. NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. London: NICE, 2011.
4. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
5. Hariprasad SM, Mieler WF, Grassi M, et al. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008;92:89-92.
6. Klein R, Moss SE, Klein BE, et al. The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 2001;119:733-740.
7. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050-1058.
8. Payakachat N, Summers KH, Pleil AM, et al. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual Life Res 2009;18:801-813.
9. The National Eye Institute. 25-Item Visual Function Questionnaire (VFQ-25).Version 2000. Available at: http:// www.rand.org/content/dam/rand/www/ external/health/ surveys-tools/vfq/vfq25-manual.pdf. Accessed 4 April 2012.
10. EuroQol - a new facility for the measurement of healthrelated quality of life. Health Policy: EuroQoL, 1990. Available from: http://www.euroqol.org (Accessed 2 November 2012).
11. EuroQol Group. EQ-5D User guide: Basic information on how to use EQ-5D, version 2.0, March 2009. Available at: http://www.euroqol.org/fileadmin/user- upload/ Documenten/PDF/User-Guide-v2-March-2009.pdf. Accessed 2 November 2012.
12. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
13. Pullenayegum EM, Tarride JE, Xie F, et al. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? Value Health 2010;13:487-494.
14. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003; 157:364-375.
15. Huang IC, Frangakis C, Atkinson MJ, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res 2008;43:327-339.
16. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-349.
17. Bharmal M, Thomas 3rd J. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 2006;9: 262-271.
18. Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res 2013;22:683-694.
19. Saarni SI, Suvisaari J, Sintonen H, et al. The healthrelated quality-of-life impact of chronic conditions varied with age in general population. J Clin Epidemiol 2007;60: 1288-1297.
20. Fenwick EK, Xie J, Ratcliffe J, et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci 2012;53:677-684.
21. Lloyd AJ, Loftus J, Turner M, et al. Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema. Health Qual Life Outcomes 2013;11:10.
22. Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol 2012;12:43.
23. Brown GC, Brown MM, Sharma S. Value-based medicine: evidence-based medicine and beyond. Ocul Immunol Inflamm 2003;11:157-170.
24. Chuang LH, Kind P. Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. PharmacoEconomics 2009;27:491-505.
25. Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health 2011;14: 354-360.
26. Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decision Making 2006;26: 18-29.
27. Rivero-Arias O, Ouellet M, Gray A, et al. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decision Making 2010;30:341-354.